Susquehanna Fundamental Investments LLC Makes New Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Susquehanna Fundamental Investments LLC bought a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 98,731 shares of the biopharmaceutical company's stock, valued at approximately $944,000. Susquehanna Fundamental Investments LLC owned 0.18% of Emergent BioSolutions as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the company. Barclays PLC grew its holdings in Emergent BioSolutions by 361.6% in the third quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company's stock valued at $329,000 after purchasing an additional 30,792 shares during the last quarter. Geode Capital Management LLC grew its stake in Emergent BioSolutions by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company's stock valued at $4,861,000 after acquiring an additional 25,776 shares during the last quarter. New York State Common Retirement Fund raised its position in Emergent BioSolutions by 41.7% during the fourth quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company's stock worth $2,928,000 after acquiring an additional 90,113 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Emergent BioSolutions by 70.9% in the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock valued at $14,722,000 after purchasing an additional 638,995 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Emergent BioSolutions by 3.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company's stock worth $7,328,000 after purchasing an additional 24,985 shares in the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent BioSolutions Trading Down 3.4 %

Shares of NYSE EBS traded down $0.17 during midday trading on Tuesday, hitting $4.78. The stock had a trading volume of 1,000,843 shares, compared to its average volume of 1,968,686. The company has a fifty day moving average price of $5.26 and a 200 day moving average price of $8.00. The company has a market capitalization of $259.89 million, a price-to-earnings ratio of -1.17 and a beta of 2.09. Emergent BioSolutions Inc. has a 1-year low of $3.84 and a 1-year high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The business had revenue of $194.70 million for the quarter, compared to analyst estimates of $254.67 million. During the same quarter in the previous year, the business posted ($0.77) EPS. On average, analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Emergent BioSolutions announced that its Board of Directors has authorized a share repurchase plan on Monday, March 31st that allows the company to buyback $50.00 million in shares. This buyback authorization allows the biopharmaceutical company to reacquire up to 19% of its stock through open market purchases. Stock buyback plans are often an indication that the company's leadership believes its shares are undervalued.

Insider Activity at Emergent BioSolutions

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now directly owns 101,100 shares of the company's stock, valued at $589,413. This represents a 25.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on EBS. StockNews.com cut Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, April 1st.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.